Search

Displaying results 2251 - 2260 of 10000 in total
  1. Drug

    Pradefovir mesylate

    go.drugbank.com/drugs/DB05478
    Investigational

    Pradefovir mesilate (previously known as MB-06886, Hepavir B and remofovir mesylate) is an orally administered small molecule compound that belongs to a novel series of phosphate and phosphonate prodrugs … Pradefovir is activated through oxidation that is mediated by cytochrome P-450 (CYP) 3A4, which is predominantly expressed in the liver.

  2. Drug

    Citrus bioflavonoids

    go.drugbank.com/drugs/DB14586
    Approved

    Mixtures: VITAMIN C 1000 MG WITH BIOFLAVONOIDS 100 MG, Kordel"s Kid"s Vitamin C 250 mg + Bioflavonoids Chewable Tablet
  3. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system.

  4. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    [A216183] Topical pediculicides generally lack adequate ovicidal activity,[A216183] including standard-of-care treatments such as [permethrin], and many require a second administration 7-10 days following … The improved ovicidal activity (90-100% _in vitro_) of abemetapir allows for a single administration, in contrast to many other topical treatments, and its novel and relatively non-specific mechanism may

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  5. Drug

    ATHX-105

    go.drugbank.com/drugs/DB06008
    Investigational

    ATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.

  6. Drug

    Dostarlimab

    go.drugbank.com/drugs/DB15627
    ApprovedInvestigational

    [L33340] This indication was granted full FDA approval on February 10, 2023.[L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours in the same month. … A prospective phase II study in patients with mismatch repair-deficient locally advanced rectal cancer resulted in all twelve patients exhibiting a complete clinical response.[A248905]

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
  7. Drug

    Dextropropoxyphene

    go.drugbank.com/drugs/DB00647
    ApprovedIllicitWithdrawn

    The levo-isomer appears to exhibit a very limited antitussive effect.

    Mixtures: Darvocet-N 100, Darvocet-N 50Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  8. Drug

    Alefacept

    go.drugbank.com/drugs/DB00092
    ApprovedWithdrawn

    Produced by CHO cells, mW is 91.4 kD. … Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of

    Categories: CD2-directed LFA-3/Fc Fusion Protein
  9. Drug

    Suzetrigine

    go.drugbank.com/drugs/DB18927
    ApprovedInvestigational

    Suzetrigine is a Na<sub>V</sub>1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na<sub>V</sub>1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain … signal transmission, making it a desirable therapeutic target for treatment of pain.

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates
  10. Drug

    Piperonyl butoxide

    go.drugbank.com/drugs/DB09350
    ApprovedVet approved

    Piperonyl butoxide is a semisynthetic derivative of safrole. … Piperonyl butoxide (PBO) is an organic compound used as a component of pesticide formulations. It is used for the treatment of head, pubic (crab), and body lice. Piperonyl butoxide is a synergist.

    Mixtures: KWELL-P %0,3 + %3 MEDİKAL ŞAMPUAN, 120 ML, Mata Piojos A Pediculicide Low FoamingCategories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Inhibitors